Pooled Data Favor Short-Course HCV Treatment
eMediNexus, 05 July 2020
remove_red_eye 710 Views
#Gastroenterology #Internal Medicine #Pathology and Lab Medicine #Pharmacist
Coronavirus Live Count Map India
remove_red_eye 710 Views
COVID-19 Vaccine Updates
#Gastroenterology #Internal Medicine #Pathology and Lab Medicine #Pharmacist
Eight weeks of glecaprevir-pibrentasvir was found to be efficacious and well tolerated in treatment-naive patients with all hepatitis C virus (HCV) genotype infections, with or without cirrhosis, reported researchers online in Clinical Gastroenterology and Hepatology.
A post-hoc analysis from eight pooled trials involving over 2,300 patients revealed that 8-week treatment with glecaprevir-pibrentasvir was associated with sustained viral response (SVR) rates of 97.6% at 12 weeks in an intent-to-treat population (ITT) and 99.3% in a modified ITT population, irrespective of cirrhotic status… (Medpage Today)
To comment on this article,
create a free account.
Sign Up
to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
.jpg)
